Médecine moléculaire et génétique

Cisplatin (CDDP) is the drug of desire towards exclusive forms of most cancers. However, tumour cells can gather resistance to the harm as a result of cisplatin, producing genetic and epigenetic modifications that result in the era of resistance and the activation of intrinsic resistance mechanisms in most cancers cells. Among them, we will discover mutations, opportunity splicing, epigenetic-pushed expression modifications, or even post-translational changes of proteins. However, the molecular mechanisms with the aid of using which CDDP resistance develops aren't clean however are believed to be multi-factorial. This article highlights an outline of cisplatin, which incorporates motion mechanism, resistance and epigenetic elements concerned in cisplatin resistance.

Cell-free DNA (cfDNA) fragments, which make up a large reservoir of data reflecting changes in the host and meta genome in real time, are regularly regenerated in body fluids. This reservoir can be used to tap assays for the diagnosis, prognosis and monitoring of a wide range of diseases, including solid tumours, foetal genetic anomalies, rejected organ transplants, infections and potentially many other conditions. Recent developments in preanalytical and analytical methods, integrated bioinformatics and machine learning algorithms have accelerated the translation of cfDNA research into practical clinical diagnostics. Nevertheless, despite these amazing developments, cfDNA continues to be a very difficult analyte to work with due to its extreme heterogeneity and fluctuation in vivo.

In this concise commentary we introduce readers to the concepts and principles of “Base editing” and “Prime editing” – two very important methodologies that nearly revolutionized the field of Genome Editing over the past few years.